Almatica Pharma
As of the edition of 20 October 2026, Almatica Pharma runs 9 drugs, 9 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Total | 9 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Escitalopram | Ended 2026 (exclusivity) | 4 |
| Duloxetine | none listed | 2 |
| Gabapentin | none listed | 1 |
| Sertraline | none listed | 1 |
| Venlafaxine | none listed | 1 |
| Citalopram | none listed | 3 |
| Zolpidem | none listed | 0 |
| Lorazepam | none listed | 1 |
| Nitrofurantoin | none listed | 0 |
A route B row is one company at one target.